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The irreversible inhibition of type I dehydroquinase (DHQ1), the third enzyme of the 
shikimic acid pathway, has been investigated by structural, biochemical and computational 
studies. Two epoxides, which are mimetics of the natural substrate, were designed as 
irreversible inhibitors of the DHQ1 enzyme and to study the binding requirements of the 
linkage to the enzyme. The epoxide with S configuration caused the covalent modification of 
the protein whereas no reaction was obtained with its epimer. The first crystal structure of 
DHQ1 from Salmonella typhi covalently modified by the S epoxide, which is reported at 1.4 
Å, revealed that the modified ligand is surprisingly covalently attached to the essential 
Lys170 by the formation of a stable Schiff base. The experimental and Molecular Dynamics 
simulation studies reported here highlight the huge importance of the conformation of the 
C3 carbon of the ligand for covalent linkage to this type of aldolase I enzyme , revealed the 
key role played by the essential His143 as a Lewis acid in this process and show the need of 
a neatly closed active site for catalysis. 
 
Introduction 
A promising approach in the search of new antimicrobial or 
antivirulence agents to combat resistant bacteria1,2 is a detailed 
knowledge of the catalytic mechanism and the binding 
determinants of enzymes involved in biosynthetic pathways or 
processes that no have mammalian homologues but they are 
essential for bacterial survival or relevant for virulence. That is 
the case of the shikimic acid pathway enzymes, through which 
chorismic acid is biosynthesized. This compound is the 
precursor in the synthesis of aromatic compounds, including the 
aromatic amino acids L-Phe, L-Tyr and L-Phe, folate cofactors, 
ubiquinone and vitamins E and K. Here we report results from 
structural, biochemical and computational studies conducted to 
improve our understanding of the irreversible inhibition of 
dehydroquinase, the third enzyme of the shikimic acid pathway. 
The dehydroquinase (3-dehydroquinate dehydratase, DHQ, EC 
4.2.1.10) is an essential enzyme in relevant pathogenic bacteria 
such as Mycobacterium tuberculosis (aroD gene), which is 
responsible for causing tuberculosis, Helicobacter pylori 
(aroD/aroQ gene), the causative agent of gastric and duodenal 
ulcers, which has also been classified as a type I carcinogen, or 
Salmonella enterica subsp. enterica serovar typhimurium 
(aroD gene), which is one of the pathogens responsible for the 
majority of human food-borne illness.3,4 There are two types of 
DHQ enzymes, namely type I DHQ (DHQ1) and type II DHQ 
(DHQ2). Both enzymes catalyze the reversible dehydration of 
3-dehydroquinic acid (1) to form 3-dehydroshikimic acid (2) 
(Scheme 1) but the reaction mechanism is completely different 
in each case.5 DHQ1, on which this work focuses, is a class I 
aldolase enzyme that catalyzes the syn elimination of water in 1 
by multi-step mechanism that involves the formation of a Schiff 
base. Nature has found in imine intermediates of this type an 
excellent way to address a wide range of complex 
transformations around the chemistry of the carbonyl and the 
amino groups.6 A good example is the wide range of reaction 
types that are catalyzed by PLP-dependent enzymes.7 The 
reaction catalyzed by DHQ1 involves the formation of a Schiff 
base between the carbonyl group of 1 and an essential Lysine 
(Lys170 in Salmonella typhi), the loss of the pro-R hydrogen at 
C2 of 1, and the acid-catalyzed elimination of the C1 hydroxyl 
group ‒ a reaction mediated by the essential histidine His143 
acting as a proton donor.5 The crystal structure of the substrate- 
and product-Schiff bases have been reported.8 Computational 
studies also suggested that the product-Schiff base hydrolysis is 
the rate-determining step.9-11 By contrast, DHQ2 catalyzes the 
anti elimination of water through the loss of the more acidic 
pro-S hydrogen from C2 of 1 via an enolate intermediate.12 
 
 
Scheme 1. Reaction catalyzed by DHQ1 and target compounds 
3–4. 
DHQ1 is present in important pathogenic bacteria such as 
Salmonella typhi, Staphylococcus aureus, Escherichia coli and 
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Salmonella enterica subsp. enterica serovar typhimurium. 
Moreover, DHQ1 may act as a virulence factor in vivo as the 
deletion of the aroD gene, which encodes DHQ1 from S. typhi 
and Shigella flexneri, have been proven to afford satisfactory 
live oral vaccines, with the latter providing monkeys with 
protection against oral challenge with live S. flexneri 2457T.13-
15 Besides these interesting properties, very few irreversible 
inhibitors16-17 of DHQ1 have been reported.18 In addition, 
although there are available crystal structures of DHQ1 in 
complex with quinic and shikimic acids,19-20 both metabolites 
of the shikimic acid pathway, structural data for DHQ1 
covalently modified by these reported irreversible inhibitors 
have not been reported to date. Such information could give an 
insight into the irreversible inhibition mechanism and would 
improve our understanding of this challenging and complex 
enzyme for the future rational design of inhibitors. To this end, 
we report here the synthesis of epoxides 34, that are mimetics 
of the natural substrate (Scheme 1). These compounds were 
designed as irreversible inhibitors of the DHQ1 enzyme and to 
study the binding requirements of the linkage to the enzyme. 
The first crystal structure of DHQ1 from S. typhi (St-DHQ1) 
covalently modified by epoxide 3 at 1.4 Å is described. 
Surprisingly, this crystal structure reveals that the epoxide 
adduct is a Schiff base. Molecular Dynamics (MD) simulation 
studies were also conducted to obtain further insights into the 
inhibition mechanism of epoxides 3–4 and to understand the 
experimentally obtained differences between both C3 epimers. 
These computational studies highlight the importance of the 
conformation of the C3 carbon of the ligand for covalent 
linkage to this type of aldolase I enzyme and revealed the key 
role of the essential His143 in this process. 
 
Results and discussion 
Synthesis of Compounds 34 
Compounds 34 were synthesized via epoxidation of an alkene 
derived from quinic acid. Several alkenes, compounds 5, were 
employed to study the diastereselectivity of the reaction (Table 
1).  
 
Table 1 Epoxidation of alkenes 5 
 
Substrate Products, yield (%) 
5a 
1R = 2R = TBS  6a, 51a -- 
5b 
1R = TMS; 2R,2R = acetalc 6b, 83b -- 
5c 
1R = 2R = H -- 7c, 65b 
5d 
1R = H; 2R,2R = acetalc 6d, 32b 7d, 40b 
aReaction conditions: UHP, TFAA, Na2HPO4, DCM, -78 ºC. 




Full protected alkenes as compounds 5a and 5b afforded 
diastereoselectively the R-isomer, compounds 6, which resulted 
from the epoxidation from the less hindered face of 5. By 
contrast, the presence of the C4 and C1 free hydroxyl groups as 
compound 5c favors the epoxidation from the Si face due to 
their orientating effect (see ESI). However, these epoxides 67 
were found to easily undergo nucleophilic ring opening under 
the basic conditions required to transform these methyl esters 
into the required acids 34. To avoid this problem, methyl ester 
5c was converted into the corresponding benzyl derivative 9 
and this group can be easily removed by hydrogenolysis 
(Scheme 2). 
The synthesis of epoxides 34 was finally achieved from 
previously described ketone 821,22. Firstly, methylenation of 
ketone 8 using Tebbe’s reagent gave alkene 5d, which was then 
deprotected under acidic conditions to afford triol 5c in 
excellent yield. Basic hydrolysis of 5c followed by alkylation 
with benzyl bromide gave benzyl ester 9. Treatment of allylic 
alcohol 9 with meta-chloroperbenzoic acid and sodium 
bicarbonate gave a chromatographically separable mixture of 
epoxides 10 and 11 in 57% and 15% yield, respectively. NOE 
experiments confirmed that the epoxidation is mainly directed 
by the orientating effect of the allylic hydroxyl group.21 
Irradiation of H8 in epoxide 10 led to enhancement of the 
signals for Hb (2.7%) and Ha (1.1%). Irradiation of H7 in 
epoxide 11 led to enhancement of the signal for Hb (1.1%). 
Finally, catalytic hydrogenolysis of the benzyl esters 10 and 11 
gave the desired epoxides 3 and 4, respectively. 
 
 
Scheme 2 Synthesis of epoxides 34. Reagents and conditions: 
a, Tebbe’s reagent, THF, RT; b, TFA/H2O (20:1), 0 °C; c, (i) 
NaOH (aq), THF, RT; (ii) K2CO3, BnBr, DMF, RT; d, 
MCPBA, NaHCO3, DCM, RT; e, H2, 10% Pd/C, MeOH, RT. 
Inhibition Activity of Compounds 34 
The inhibitory properties of compounds 34 against St-DHQ1 
were tested. Both epoxides proved to have a highly 
differentiated activity against St-DHQ1. Epoxide 4 proved to be 
a weak inhibitor with an IC50 of 1 mM. A monitoring by 
1H 
NMR spectroscopy of a sample of epoxide 4 in the presence of 
St-DHQ1 revealed that no hydrolysis of the epoxide occur after 
72 h incubation (Figure S2 of ESI). By contrast, epoxide 3 was 
found to be a time-dependent irreversible inhibitor of the 
enzyme (Figure 1). Thus, a 274 µM concentration of epoxide 3 
caused 50% enzyme inactivation in 30 minutes and after 
approximately 2 hours 75% inactivation was obtained. 
Inhibition is also observed at lower concentrations of 3 (110 
µM) but it less efficient. Higher concentrations of 3 provide a 
barely detectable enzymatic activity after approximately 2 
hours. It is important to highlight that hydrolysis of the two 
epoxides was not observed in the absence of enzyme under the 
assay conditions. In order to obtain further details of the 
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mechanism of action of these inhibitors, structural and MD 
simulation studies were carried out. 
 
Figure 1. Variation of the enzymatic activity of St-DHQ1 (1 
µM) with time without () and after incubation with epoxide 3 
[() 110 µM, () 274 µM and () 825 µM]. Results are the 
average for three observations. Assay conditions were PPB (50 
mM, pH 7.2) at 25 °C. The curves were fitted by using the 
GraFit 5 program (Erithacus Software Ltd.). 
Structural studies 
The crystal structure of St-DHQ1 covalently modified by its 
inhibitor 3 was obtained by co-crystallization and it was 
determined at 1.4 Å. Crystals were cryo-protected with 
crystallization solution supplemented with 20% glycerol and 
samples were flash-frozen by rapid immersion in liquid 
nitrogen. X-ray diffraction data were collected from crystals 
cryo-cooled in a stream of cold nitrogen gas (100 K) at ambient 
pressure using synchrotron radiation and the data were 
subsequently processed. The structure was determined by 
molecular replacement using the previously described structure 
of St-DHQ1 covalently attached to the active site by Lys170, 
which was obtained by sodium borohydride reduction of the 
corresponding product-Schiff base intermediate (PDB entry 
1QFE)5 as a search model, and the structure was refined. A 
summary of the statistical data following data reduction and 
processing is given in Table 2. 
The resulting St-DHQ1/3 adduct crystallized with two copies in 
the asymmetric unit (designated as chains A and B) with 0.301 
Å rms difference after superposition of Cα-atom pairs (Figure 
S3 of ESI). The structure was refined with good geometric 
parameters and clear electron density is visible for all amino 
acids with the exception of residues 228236 in chain A, which 
are located on the flexible substrate-covering loop and are not 
visible in this chain. In addition, the ligand cannot be observed 
in chain A. Comparison of chain B of the crystal structure 
reported here with that in the previously described structure of 
the reduced form of the product-Schiff base intermediate (PDB 
entry 1QFE)5 shows that both structures are virtually identical 
(0.262 Å rms difference after superposition of Cα-atom pairs). 
In both cases, the flexible loop is in the closed conformation. 
The closure of this loop forms an additional hydrophobic layer 
on top of the active site and this is composed of conserved 
residues Phe145, Met205 and Ala172. MD simulation studies 
have shown that the sealing of the active site by the entry of the 
Phe145 side chain inside the site to create a lid is the last step in 
the formation of the Michaelis complex and it does not occur 
until the active site is neatly closed by the substrate-covering 
loop.24 Met205 seems to be involved in keeping the Phe145 
side chain inside the active site by an attractive interaction 
derived from its location at the edge of the phenyl ring. In this 
arrangement, the active site is shielded from the solvent 
environment. 
 
Table 2. Crystallographic data collection and refinement 
statistics for the St-DHQ1/3 adducta 
Data processinga 
space group P21 
cell parameters (a, b, c), Å a = 60.59, b = 44.47, c = 84.98 
(β = 95.2°) 
wavelength (Å) 0.87290 
detector Dectris PILATUS 6M 
observed reflectionsb 307905 (26338)c 
resolution range (Å) 47.17 – 1.40 (1.48 – 1.40) 
Wilson B (Å2) 9.2 
multiplicity 3.6 (2.7) 
completeness 0.960 (0.761) 
Rmerge 0.063 (0.216) 
Refinementd 
resolution range (Å) 47.21 – 1.40 (1.48 – 1.40) 
reflections used in 
refinementc 
81186 (9343) 
reflections used for Rfree 4293 (478) 
R factore 0.120 (0.152) 
Rfree
f 0.155 (0.214) 











PDB accession code 4CLM 
aResults from SCALA31. bNo sigma cut-off or other 
restrictions were used for inclusion of reflections. cValues in 
parentheses are for the highest resolution bin, where 
applicable. dResults from REFMAC37. eR-factor = 
||Fobs(hkl)| - |Fcalc(hkl)|| / |Fobs(hkl)|. fAccording to 
Brünger36. gAccording to the program MOLPROBITY38. The 
percentages indicated are for residues in favored and total 
allowed regions, respectively.  
 
Unbiased, calculated electron density maps showed clear 
electron density for the enzyme-modified inhibitor molecule 3 
(Figure 2). The cyclohexane ring of this compound occupies 
approximately the same site as the cyclohexene ring of the 
reduced form of the product-Schiff base in PDB entry 1QFE5 
The reported crystal structure shows that the compound is 
covalently attached to Lys170, which shows two possible 
arrangements (Figure S4 of ESI), and it binds to the active site 
by a salt-bridge between its carboxylate group and the 
guanidinium group of the conserved Arg213, which is the key 
residue for carboxylate recognition, along with a bidentate 
hydrogen bond between the carboxylate group of the conserved 
Glu46 and the C4 and C5 hydroxyl groups of the inhibitor 
molecule. The latter compound is also anchored in the active 
site by several additional hydrogen bonds. Thus, the C4 
hydroxyl group of the inhibitor interacts by hydrogen bonding 
with the guanidinium group of the conserved Arg82 and a water 
molecule (WAT173) that is found in several crystal structures 
making a bridge between Asp114 and Glu46, probably to avoid 
time (h)
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repulsion between the two residues. The C5 hydroxyl group 
establishes three additional hydrogen bonds, one with the 
guanidinium group of the conserved Arg48 and two with the 
side chains of Ser232 and Ser21, both of which are located in 
the loop that closes the active site. The latter interactions, along 
with the hydrogen bond between the carboxylate group of the 
modified inhibitor and the side chain of a conserved Gln236, 
contribute to close the active site tightly. Moreover, the C1 
hydroxyl group of the modified inhibitor and the guanidinium 
group of Arg82 interact by a bridging water molecule 
(WAT285). Finally, this structure also revealed key CH-π 
interactions between the phenyl ring of the conserved Phe225 




Figure 2. Crystal structure of the St-DHQ1 covalently modified 
by epoxide 3. (A) Unbiased electron density for the modified 
inhibitor 3 (yellow) and its covalent attachment to Lys170 of 
St-DHQ1 (chain B, gray). From the model obtained by 
molecular replacement and before inclusion of the inhibitor 
molecule, refinement was performed to obtain unbiased density 
for the inhibitor molecule and other model changes. A 
maximum-likelihood weighted 2Fo – Fc map contoured at 1σ is 
shown up to 1.6 Å around the inhibitor molecule (red) and 
water molecule W285 (blue). The distance between C3 atom 
and W285 is shown as dashed lines (black). The final model, 
including the inhibitor molecule, is superimposed onto the map. 
(B) Interactions of the modified inhibitor 3 with St-DHQ1. 
Hydrogen bonding and electrostatic interactions (blue) between 
the ligand and the St-DHQ1 are shown. Relevant residues are 
shown and labeled. 
 
Surprisingly, the crystal structure reported here reveals that the 
ligand is covalently attached to the enzyme as a Schiff base 
rather than by the expected hydroxyl amino derivative that 
would be obtained after nucleophilic ring opening of the 
epoxide group in 3 by Lys170 as no electron density was 
observed for the corresponding C3 hydroxyl group (Figure 2A). 
This finding suggests that additional chemical modifications 
took place. Also remarkable is the stability against hydrolysis 
of the experimentally obtained Schiff base. In this context, 
covalent attachment of DHQ1 from E. coli to the product 
molecule, which is obtained by borohydride reduction of the 
product-Schiff base, also proved to cause a dramatic increase in 
the stability of the protein.25 We believe that this process might 
also occur with the St-DHQ1/3 adduct and this would explain 
its stability against hydrolysis. In an effort to gain a further 
insight into the inhibition mechanism of epoxides 3–4 and to 
understand the experimentally observed differences in 
inhibitory properties, MD simulation studies were conducted, 
as it would be discussed below. 
Molecular dynamics simulation studies 
The binding modes of compounds 34 with St-DHQ1 were 
initially studied using GOLD 5.226 with the enzyme coordinates 
found in chain B of the St-DHQ1/3 adduct crystal structure and 
they were further analyzed by MD simulation studies (10 ns). 
The corresponding Michaelis complex, St-DHQ1/1, was also 
studied. The monomer in aqueous solution using the molecular 
mechanics force field AMBER27 was employed. On the basis of 
results from MD simulations performed with the St-DHQ1/3 
adduct and due to mechanistic considerations, a dual 
protonation of His143 and a deprotonated Lys170 was 
considered. The binding free energies of compounds 34 in the 
active site of St-DHQ1 were also calculated using the 
Molecular Mechanics Poisson–Boltzmann Surface Area 
(MM/PBSA)28 approach in explicit water (GB), as implemented 
in AMBER. These calculations revealed that epoxide 3 has a 
higher affinity for the enzyme than its epimer 4, a finding that 
is consistent with the experimental results (Table S1 of ESI). 
It was found that the epoxide 3, which should bind to the active 
site as the natural substrate (Figures 3A-3B), remained very 
stable during the 10 ns of simulation (Figures 3A, S5 and S6). 
In this binding mode the oxygen atom of the epoxide ring in 3 
would be located in close contact with the essential His143 side 
chain and, to a lesser extent, with the guanidinium group of 
Arg82 as the natural substrate. Lys170, which is located in the 
opposite face, is also close to the methylene group of the 
epoxide moiety in 3. This can be clearly visualized by 
analyzing the variation of the distances involving the oxygen 
atom and the methylene group of the epoxide moiety in 3 and 
the HE2 atom of His143 and NZ atom of Lys170, respectively, 
during the whole simulation (Figure 3E). Comparison of the 
variation of the distances involving the equivalent reactive 
centers (carbonyl group) of the natural substrate in the 
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Figure 3. Binding mode of epoxides 3˗4 obtained by MD simulation studies. (A-C) Comparison of results after minimization and 
prior simulation (orange) and after the dynamic simulation (cyan) with epoxides 3 (A) and 4 (C) in the active site of St-DHQ1. 
Note how epoxide 4 caused the opening of the flexible loop by more than 4 Å (shown as dashed lines in magenta) while no 
significant changes were observed in the binding mode of epoxide 3. Relevant side chain residues are shown and labeled. (B) 
Comparison of the binding mode of the natural substrate (pink) and epoxide 3 (cyan). (D-F) Variation of selected distances in the 
Michaelis and St-DHQ1/3-4 binary complexes during 10 ns simulation: (D) oxygen atom of epoxide 4 and NZ atom of Lys170 
ARTICLE Journal Name 
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(d1); (E) oxygen atom of epoxide 3 and HE2 atom of His143 (d3) and methylene group of epoxide ring in 3 and NZ atom of 
Lys170 (d2); (F) oxygen atom of carbonyl group in 1 and HE2 atom of His143 (d5) and carbon atom of carbonyl group in 1 and 
NZ atom of Lys170 (d4). 
 
 
Scheme 3 Proposed mechanism for the covalent modification of St-DHQ1 by 3.
During the simulation, a significant movement of His143 side 
chain was observed. Even so, during most of the simulation, the 
guanidinium group of His143 is closer to the epoxide oxygen 
than to the carbonyl group of the natural substrate (Figures 3E 
and 3F). Covalent attachment of 3 would probably occur when 
the two catalytic residues, His143 and Lys170, are very close to 
the epoxide moiety. In this arrangement, His143 might act as a 
Lewis acid by activating and correctly positioning the epoxide 
group of 3 for nucleophilic attack by the -amino group of the 
essential Lys170 (Scheme 3). The resulting intermediate I could 
then be deprotonated by the neutral His143 to give the 
corresponding amino alcohol II. The final steps would be the 
acid-catalyzed elimination of the tertiary hydroxyl group – a 
reaction mediated by His143 acting as a proton donor to afford 
enamine III. Considering the type of residues located in the 
proximity of the methylene group of II and their disposition, an 
hydroxide group generated from water molecule W173, which 
is observed in all the available crystal structures, seems to be 
the most plausible base for the elimination reaction. W173 has 
its protons engaged in hydrogen bonding with the carboxylate 
oxygens of Glu46 and Asp114, and one of its oxygen’s lone 
pairs accepting a hydrogen bond from the guanidinium group of 
Arg48. On the basis of results from MD simulations performed 
with the St-DHQ1/3 adduct and the microenvironment around 
the functional group, Asp114 might be the residue responsible 
for the deprotonation of W173. The resulted hydroxide group 
might be stabilized by an electrostatic interaction with the 
guanidinium group of Arg48. Finally, the resulted enamine III 
could be in equilibrium with the experimentally observed Schiff 
base. 
In contrast to the above, the MD simulation studies conducted 
with epoxide 4 showed that this compound, when bound to the 
active site of St-DHQ1, caused the opening of the flexible 
substrate-covering loop by up to 4.3 Å and a displacement of 
the His143 side chain from the epoxide moiety (Figure 3C and 
S5). During the simulation, the amino group of the Lys170 side 
chain remains in close contact with the oxygen atom of the 
epoxide ring and with the NE2 group of the His143 side chain 
(Figure 3D). An extended conformation of the Lys170 side 
chain is also observed. Significant motions in the position of 
the Phe145 and Met205 side chains, which are located in the 
loop that acts as a lid for the active-site cleft, and the entrance 
of two water molecules in proximity to the epoxide group in 4 
were observed. In this arrangement, the active site is not 
shielded from the solvent environment, which is required for 
the enzymatic reaction, and no activation of the epoxide ring by 
His143 might occur. Instead, a strong hydrogen bonding 
interaction between the ɛ-amino group of the essential Lys170 
and the oxygen atom of the epoxide ring was observed. These 
findings might explain why epoxide 4 is unable to cause the 
covalent modification of the enzyme, as experimentally 
observed. 
Therefore, our results suggest that the covalent linkage of these 
ligands to the enzyme requires the activation by His143 as 
Lewis acid to allow the nucleophilic attack of Lys170 for the 
opposite face of the leaving group. Moreover, DHQ1 seems to 
be specifically designed to perform a nucleophilic attack of 
Lys170 by the Si face of the carbonyl group in 1 after activation 
by His143 from the opposite face. Moreover, a closed 
conformation of the substrate-covering loop is also required for 
the covalent linkage to DHQ1. 
Conclusions and final remarks 
The results of the present study show that the epoxide 3 is a 
good mimetic of the natural substrate because its epoxide 
moiety has the appropriate stereochemistry to be activated by 
His143 and it causes the irreversible inhibition of the DHQ1 
enzyme by covalent modification. By contrast, its epimer, 
epoxide 4, is a weak reversible competitive inhibitor of the 
enzyme that would cause the opening of the flexible substrate-
covering loop. The epoxide moiety of 4 would interact by 
hydrogen bonding with the -amino group of the essential 
Lys170 that would be in an extended conformation. The crystal 
structure reported here revealed that the modified ligand 3 is 
covalently attached to the essential Lys170 by forming a stable 
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Schiff base after several chemical modifications. The results of 
MD simulation studies suggest that the resulting St-DHQ1/3 
adduct is obtained by activation of His143 followed by 
nucleophilic ring opening of the epoxide and subsequent 
dehydration and isomerization reactions. To our knowledge, 
this is the first Schiff base of an aldolase enzyme obtained from 
an epoxide that has been described. 
The structural and computational studies reported provide 
strong evidence that the enzyme appears to be designed to form 
the substrate-Schiff base by activation and correct positioning 
of the oxygen atom of the ketone group in 1 by His143 and 
subsequent nucleophilic attack by Lys170 from Si face of the 
ketone group. This process requires a shielded active site from 
the solvent environment by the substrate-covering loop. The 
results presented here improve our understanding of some of 
the determinants of irreversible inhibition and provide new 
insights to be considered in the structure-based design of 




All starting materials and reagents were commercially available and 
were used without further purification. 1H NMR spectra (250, 300, 
400 and 500 MHz) and 13C NMR spectra (63, 75, 100 and 125 MHz) 
were measured in deuterated solvents. J values are given in Hertz. 
NMR assignments were carried out by a combination of 1 D, COSY, 
and DEPT-135 experiments. FT-IR spectra were recorded as NaCl 
plates or KBr discs.     
   = values are given in 10-1 deg cm2 g-1. All 
procedures involving the use of ion-exchange resins were carried out 
at room temperature using Milli-Q deionized water. Amberlite IR-
120 (H+) (cation exchanger) was washed alternately with water, 10% 
NaOH, water, 10% HCl, and finally water before use. 
Methyl (1R,3S,4S,6R,9R)-9-hydroxy-3,4-dimethoxy-3,4-
dimethyl-7-methylene-2,5-dioxabicyclo[4.4.0]decan-9-
carboxylate (5d). A solution of Tebbe's reagent in toluene (22 
mL, 11.07 mmol, ca. 0.5 M) was added slowly to a stirred 
solution of the ketone 821 (3.2 g, 10.06 mmol) in dry THF (50 
mL) under argon at 0 ºC. The mixture was stirred at room 
temperature for 2 h and then was diluted with diethyl ether (125 
mL). Aqueous sodium hydroxide (0.1 M, 10–20 drops) was 
added very slowly and then the mixture was dried (MgSO4), 
filtered through Celite and evaporated under reduced pressure. 
The residue was purified by flash column chromatography, 
eluting with (40:60) ethyl acetate/hexanes, to yield alkene 5d 
(2.05 g, 67%) as a colorless oil. 1H NMR (300 MHz, CDCl3) 
5.29 (q, J = 1.8 Hz, 1H, CHH), 4.94 (q, J = 1.8 Hz, 1H, 
CHH), 4.08 (br d, J = 9.0 Hz, 1H, H6), 3.88 (m, 1H, H1), 3.80 
s, 3H, OCH3), 3.26 (s, 3H, OCH3), 3.22 (s, 3H, OCH3), 2.90 
(s, 1H, OH), 2.63 (br d, J = 13.8 Hz, 1H, H8ax), 2.34 (dd, J = 
13.8 and 3.0 Hz, 1H, H8eq), 2.08 (dd, J = 12.9 and 12.0 Hz, 1H, 
H10ax), 1.94 (ddd, J = 12.9, 4.8 and 3.0 Hz, 1H, H10eq),s, 
3H, CH3) and s, 3H, CH3) ppm. 
13C NMR (75 MHz, 
CDCl3) 175.3 (C), 139.0 (C), 109.7 (CH2), 99.7 (C), 99.4 
(C), 74.1 (C), 72.3 (CH), 67.9 (CH), 52.9 (OCH3), 47.7 
(OCH3), 47.7 (OCH3), 42.8 (CH2), 37.8 (CH2) and 
17.62×CH3) ppm. 
Methyl (1S,3R,4R)-1,3,4-trihydroxy-5-methylenecyclohexane-
1-carboxylate (5c). A stirred solution of acetal 5d (1.0 g, 3.29 
mmol) in a (20:1) TFA/H2O solution (33 mL) was stirred at 
room temperature for 15 min. The solvent was removed under 
reduced pressure and the residue resulted was purified by flash 
chromatography eluting with ethyl acetate to afford compound 
5c (630 mg, 95%) as a colorless oil.     
   = 3° (c 1.0, MeOH). 
1H NMR (250 MHz, CDCl3) 5.25 (s, 1H, CHHC), 4.99 (s, 
1H, CHHC), 3.97 (d, J = 8.7 Hz, 1H, H4), 3.81 (s, 3H, OCH3), 
3.74 (m, 1H, H3), 2.95 (s, 1H, OH), 2.64 (d, J = 13.7 Hz, 1H, 
H6ax), 2.39 (dd, J = 13.7 and 2.7 Hz, 1H, H6eq), 2.13 (ddd, J = 
13.0, 5.0 and 3.0 Hz, 1H, H2eq) and 1.99 (dd, J = 13.0 and 11.2 
Hz, 1H, H2ax) ppm.
 13C NMR (75 MHz, CD3OD) : 176.7 (C), 
145.1 (C), 110.8 (CH2), 78.2 (CH), 75.5 (C), 72.7 (CH), 53.0 
(CH3), 43.4 (CH2) and 42.0 (CH2) ppm. IR (film) ʋ: 3400 (OH) 
and 1730 (CO) cm-1. MS (ESI) m/z = 225 (M + Na+). HRMS 
calcd for C9H14O5Na (M + Na
+): 225.0733; found, 225.0737. 
Benzyl (1S,3R,4R)-1,3,4-trihydroxy-5-methylenecyclohexane-
1-carboxylate (9). A stirred solution of methyl ester 5c (400 mg, 
1.98 mmol) in THF (19.8 mL) was treated with aqueous NaOH 
(4.0 mL, 1.98 mmol, 0.5 M). After stirring for 30 min, THF 
was concentrated under reduced pressure and the aqueous 
solution was diluted with Milli-Q water and ethyl acetate. The 
organic layer was separated and the aqueous layer was washed 
with ethyl acetate (×2). The aqueous extract was liophilized to 
give the corresponding sodium salt (410 mg, 99%) as a 
colorless oil, which was disolved in dry DMF (19.5 mL) and 
treated, at room temperature and under argon, with K2CO3 (810 
mg, 5.86 mmol). The resultant solution was treated with benzyl 
bromide (2.7 mL, 15.62 mmol) and after stirring for 2 h, ethyl 
acetate and brine were added. The organic layer was separated 
and the aqueous layer was extracted with ethyl acetate (×5). 
The combined organic extracts were dried Na2SO4 (anh.), 
filtered and concentrated under reduced pressure. The resulted 
residue was purified by flash chromatography eluting with 
(50:50) ethyl acetate/hexanes to yield benzyl ester 9 (439 mg, 
81%) as a colorless oil.     
   = +10º (c 1.8, CHCl3). 
1H NMR 
(300 MHz, CDCl3) 7.32 (m, 5H, 5×ArH), 5.21 (s, 1H, CHH), 
5.19 (d, J = 12.3 Hz, 1H, OCHH), 5.14 (d, J = 12.3 Hz, 1H, 
OCHH), 4.88 (s, 1H, CHH), 3.90 (d, J = 9.0 Hz, 1H, H4), 3.73 
(m, 1H, H3), 2.57 (d, J = 14.1 Hz, 1H, H6ax), 2.34 (dd, J = 14.1 
and 2.4 Hz, 1H, H6eq), 2.13 (m, 1H, H2eq) and 1.95 (dd, J = 
13.2 and 11.4 Hz, 1H, H2ax) ppm. 
13C NMR (75 MHz, CDCl3) 
 174.8 (C), 142.4 (C), 135.0 (C), 128.6 (2×CH), 128.5 (C), 
128.1 (2×CH), 110.6 (CH2), 77.0 (CH), 74.1 (C), 71.9 (CH), 
67.7 (OCH2), 42.6 (CH2) and 40.6 (CH2) ppm. IR (film) ʋ: 
3398 (OH) and 1730 (CO) cm-1. MS (ESI) m/z = 301 (M + 
Na+). HRMS calcd for C15H18O5Na (M + Na
+): 301.1046; 
found, 301.1034. 
Epoxidation of alkene 9: benzyl (3S,5R,7R,8S)-5,7,8-
trihydroxy-1-oxaspiro[2.5]octane-5-carboxylate (10) and 
benzyl (3R,5R,7R,8S)-5,7,8-trihydroxy-1-
oxaspiro[2.5]octane-5-carboxylate (11). A stirred solution 
of alkene 9 (200 mg, 0.72 mmol) in dry dichloromethane (7.0 
mL), at room temperature and under argon, was treated with 
MCPBA (130 mg, 1.80 mmol) and sodium bicarbonate (90 mg, 
1.08 mmol). After stirring for 20 h, potassium carbonate was 
added and the suspension was filtered. The filtrate and the 
washings were concentrated under reduced pressure. The 
resulted residue was purified by flash chromatography eluting 
with a gradient of ethyl acetate/hexanes [(75:25) to (100:0)] to 
afford epoxides 10 (120 mg, 57%) and 11 (31 mg, 15%). The 
stereochemistry of new chiral center of both epoxides was 
determined by NOE experiments. The stereochemistry of C1 in 
10 is supported by the enhancement of the Ha (1.1%) and Hb 
(2.7%) signals resulted of the inversion of H8 signal. The 
enhancement of the Hb signal resulted of the inversion of H7 
signal (1.1%) supports the C1 stereochemistry of 11.  
10: Colorless oil.     
   = 4º (c 1.2, MeOH). 1H NMR (300 
MHz, CD3OD) : 7.34 (m, 5H, 5×ArH), 5.20 (d, J = 12.3 Hz, 
1H, CHHPh), 5.15 (d, J = 12.3 Hz, 1H, CHHPh), 3.94 (ddd, J = 
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10.8, 9.3 and 4.5 Hz, 1H, H7), 3.59 (d, J = 9.3 Hz, 1H, H8), 
2.87 (d, J = 5.1 Hz, 1H, CHHO), 2.48 (d, J = 14.7 Hz, 1H, 
H4ax), 2.41 (d, J = 5.1 Hz, 1H, CHHO), 2.19 (ddd, J = 13.5, 4.5 
and 3.0 Hz, H6eq), 1.92 (dd, J = 13.5 and 10.8 Hz, H6ax) and 
1.59 (dd, J = 14.7 and 3.0 Hz, H4eq) ppm. 
13C NMR (75 MHz, 
CD3OD) : 174.3 (C), 135.1 (C), 128.6 (2×CH), 128.5 (CH), 
128.2 (2×CH), 74.5 (C), 72.6 (CH), 69.3 (CH), 67.6 (CH2), 
58.0 (C), 46.3 (CH2), 40.5 (CH2) and 39.6 (CH2) ppm. IR (film) 
ʋ: 3417 (OH) and 1732 (CO) cm-1. MS (ESI) m/z = 317 (M + 
Na+). HRMS calcd for C15H18O6Na (M + Na
+): 317.0996; 
found, 317.1001. 
11: White solid. Mp: 108111 °C.     
   = +7° (c 1.3, CHCl3). 
1H NMR (300 MHz, CD3OD) : 7.33 (m, 5H, 5×ArH), 5.20 (d, 
J = 12.6 Hz, 1H, PhCHHO), 5.16 (d, J = 12.6 Hz, 1H, 
PhCHHO), 3.80 (m, 1H, H7), 3.59 (d, J = 9.3 Hz, 1H, H8), 3.09 
(dd, J = 5.4 and 1.2 Hz, 1H, CHHO(Hb)), 2.58 (d, J = 5.4 Hz, 
1H, CHHO(Ha)), 2.38 (dd, J = 13.5 and 1.2 Hz, 1H, H4ax), 2.13 
(ddd, J = 13.2, 4.5 and 3.0 Hz, 1H, H6eq), 1.88 (dd, J = 13.2 and 
11.4 Hz, 1H, H6ax) and 1.49 (dd, J = 13.5 and 3.0 Hz, 1H, H4eq) 
ppm. 13C NMR (75 MHz, CD3OD) : 175.6 (C), 133.8 (C), 
129.6 (2×CH), 129.4 (CH), 129.3 (2×CH), 75.2 (C), 75.1 (CH), 
71.1 (CH), 68.2 (OCH2), 59.4 (C), 50.6 (OCH2), 41.9 (CH2) 
and 41.6 (CH2) ppm. IR (KBr) ʋ: 3421 (OH) and 1733 (CO) 
cm-1. MS (ESI) m/z = 317 (M + Na+). HRMS calcd for 
C15H18O6Na (M + Na
+): 317.0996; found, 317.0984. 
(3S,5R,7R,8S)-5,7,8-Trihydroxy-1-oxaspiro[2.5]octane-5-
carboxylic acid (3). A suspension of benzyl ester 10 (40 mg, 
0.14 mmol) and Pd/C (4 mg, 5%) in ethyl acetate (30 mL), was 
stirred at room temperature and under hydrogen atmosphere for 
8 h. After removal of the hydrogen atmosphere, the suspension 
was filtered over a plug of Celite. The filtrate and the washings 
(ethyl acetate) were concentrated under reduced pressure to 
afford acid 3 (22 mg, 77%) as a white solid. Mp: 150153 °C 
(dec.).     
   = +12° (c 2.5, MeOH). 1H NMR (300 MHz, 
CD3OD) : 3.94 (ddd, J = 11.1, 9.3 and 4.5 Hz 1H, H7), 3.62 
(d, J = 9.3 Hz, 1H, H8), 2.90 (d, J = 5.1 Hz, 1H, CHHO (Ha)), 
2.52 (d, J = 14.7 Hz, 1H, H4ax), 2.42 (d, J = 5.1 Hz, 1H, 
CHHO(Hb)), 2.17 (ddd, J = 13.2, 4.5 and 3.0 Hz, 1H, H6eq), 
1.92 (dd, J = 13.2 and 11.1 Hz, 1H, H6ax) and 1.56 (dd, J = 14.7 
and 3.0 Hz, 1H, H4eq) ppm.
 13C NMR (75 MHz, CD3OD) : 
178.0 (C), 76.5 (C), 73.9 (CH), 70.3 (CH), 59.1 (C), 46.8 
(OCH2), 42.1 (CH2) and 40.7 (CH2) ppm. IR (KBr) ʋ: 3303 
(OH) and 1716 (CO) cm-1. MS (ESI) m/z = 203 (M  H). 
HRMS calcd for C8H11O6 (M  H): 203.0561; found, 203.0556. 
(3R,5R,7R,8S)-5,7,8-Trihydroxy-1-oxaspiro[2.5]octane-5-
carboxylic acid (4). A suspension of benzyl ester 11 (20 mg, 
0.07 mmol) and Pd/C (2 mg, 5%) in ethyl acetate (15 mL), was 
stirred at room temperature and under hydrogen atmosfere for 8 
h. After removal of the hydrogen atmosphere, the suspension 
was filtered over a plug of Celite. The filtrate and the washings 
(ethyl acetate) were concentrated under reduced pressure to 
afford acid 4 (20 mg, 82%) as a white solid. Mp: 128131 °C 
(dec.).     
   = 6° (c 1.8, MeOH). 1H NMR (250 MHz, 
CD3OD) : 3.82 (ddd, J = 11.5, 9.2 and 5.0 Hz 1H, H7), 3.62 
(d, J = 9.2 Hz, 1H, H8), 3.11 (dd, J = 5.3 and 1.5 Hz, 1H, 
CHHO), 2.60 (d, J = 5.3 Hz, 1H, CHHO), 2.41 (dd, J = 13.5 
and 1.5 Hz, 1H, H4ax), 2.12 (ddd, J = 13.5, 5.0 and 3.0 Hz, 1H, 
H6eq), 1.90 (dd, J = 13.5 and 11.5 Hz, 1H, H6ax) and 1.48 (dd, J 
= 13.5 and 3.0 Hz, 1H, H4eq) ppm.
 13C NMR (63 MHz, 
CD3OD) : 177.9 (C), 75.3 (CH), 74.8 (C), 71.2 (CH), 59.6 (C), 
50.6 (OCH2), 42.0 (CH2) and 41.7 (CH2) ppm. IR (KBr) ʋ: 
3396 (OH) and 1702 (CO) cm-1. MS (ESI) m/z = 227 (M + 
Na+). HRMS calcd for C8H12O6Na (M + Na
+): 227.0526; found, 
227.0530. 
Dehydroquinase assays. The St-DHQ1 enzyme was purified as 
described previously.29 Concentrated solutions of St-DHQ1 
(0.85 mg mL-1, 30.74 µM) were stored in potassium phosphate 
buffer (50 mM) and DTT (1 mM) at pH 6.6 at 80 °C. When 
required for assays, aliquots of the enzyme stocks were diluted 
into water and buffer and stored on ice.  Dehydroquinase was 
assayed in the forward direction by monitoring the increase in 
absorbance at 234 nm in the UV spectrum due to the 
absorbance of the enone-carboxylate chromophore of 3-
dehydroshikimic acid (2) (/M-1 cm-1 12 000). Standard assay 
conditions were PPB (50 mM, pH 7.2) at 25 °C. Each assay 
was initiated by addition of the substrate. Solutions of 3-
dehydroquinic acid (1) were calibrated by equilibration with 
DHQ1 and measurement of the change in the UV absorbance at 
234 nm due to the formation of the enone-carboxylate 
chromophore of 3-dehydroshikimic acid (2). Under assay 
conditions, the kinetic parameters of St-DHQ1 were Km = 24  
3 µM and kcat = 1.1  0.1 s
-1. 
Inhibition assays. 15 µL of St-DHQ1 enzyme stocks (30.7 µM, 
0.85 mg mL-1) was independently incubated with 4, 10 and 30 
µL of aqueous stocks solutions of epoxide 3 (13.7 mM) in 50 
mM PPB at pH 7.2 at 25 °C in a total volume of 500 µL. 
Epoxide 3 inhibition assay concentrations: 110, 274 and 825 
µM, respectively. Under the same assay conditions, the activity 
of the St-DHQ1 enzyme was simultaneously followed as a 
control in the absence of epoxide 3. The activity was 
progressively determined over 24 h period under the standard 
assay conditions (see above) using aliquots (8 µL) from the 
incubation samples and the control and 50 µL of a 0.27 mM 
solution of 3-dehydroquinic acid (1). The initial rates at the 
above mentioned fixed enzyme, epoxide 3 and substrate 
concentrations were measured and plotted against time. The 
IC50 of compound 4 against St-DHQ1 was obtained by 
measuring the initial rates at fixed enzyme and substrate 
concentrations (Km) in the absence and in the presence of 
various inhibitor concentrations. 
Crystallization of St-DHQ1/3 adduct. St-DHQ1 was 
concentrated to 8 mg mL-1 in 10 mM Tris.HCl pH 7.4 and 40 
mM potassium chloride. Compound 3 was dissolved at 0.25 M 
in methanol and added at a ratio of 1:20 (v/v) to the protein 
solution to give a solution of approximately 10 equivalents of 3 
per protein monomer. Plate-shaped crystals of up to 0.1 mm × 
0.1 mm of the St-DHQ1/3 adduct were obtained after four 
weeks of vapor diffusion in sitting drops comprised of 2.0 L 
protein/inhibitor solution mixed with 2.0 L reservoir solution 
against 0.15 mL reservoirs containing 34% (w/v) 
polyethyleneglycol 4000 and 0.1 M citrate/phosphate pH 5.6. 
Structure determination of St-DHQ1/3 adduct. Crystals were 
mounted into cryoloops and directly flash frozen by rapid 
immersion in liquid nitrogen. X-ray diffraction data for St-
DHQ1/3 adduct was collected on beamline ID23-2 (ESRF, 
Grenoble, France) from a crystal maintained at 100 K. The 
diffraction data were processed, scaled, corrected for absorption 
effects and the crystal unit-cell parameters calculated by global 
refinement using XDS,30 SCALA31 and other programs within 
the CCP4 software suite.32 The structure was solved by 
molecular replacement, using the program MOLREP33 with a 
search model generated from PDB entry 1QFE5. Inhibitor´s 
structure and geometrical restraints were generated with the 
PRODRG2 server34 and it was manually placed during the 
model building, which was performed with COOT.35 
Reflections for calculating Rfree36 were selected randomly. The 
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refinement of the models was performed with REFMAC37 and 
final structure validation was performed with 
MOLPROBITY.38 The data collection, refinement and model 
statistics are summarized in Table 2. Structure figures were 
prepared using PYMOL.39  
Molecular dynamics simulations. Ligand minimization. 
Ligand geometries were optimized using a restricted Hartree–
Fock (RHF) method and a 6–31G(d,p) basis set, as 
implemented in the ab initio program Gaussian 09.40 The 
charge distribution for each ligand studied was obtained by 
fitting the quantum mechanically calculated (B3LYP/cc-pVTZ 
and IEF-PCM as solvation model) molecular electrostatic 
potential (MEP) of the geometry-optimized molecule to a point 
charge model, as implemented in the assisted model building 
with energy refinement (AMBER)41 suite of programs. The 
missing bonded and non-bonded parameters were assigned, by 
analogy or through interpolation from those already present in 
the AMBER database (GAFF).42  
Generation and minimization of the DHQ1-ligand complexes. 
Simulations were carried out using the enzyme geometries 
found in the crystal structure of St-DHQ1/3 adduct. The 
monomer (chain B) was used for these studies. For St-
DHQ1/3˗4 binary complexes, the covalently linked ligand was 
manually replaced by epoxides 3–4, respectively. 
Crystallographic water molecules were maintained. Hydrogens 
were added to the protein using the web-based PROPKA3.1 
server,43 which assigned protonation states to all titratable 
residues at the chosen pH of 7.0. However, δ and/or ε 
protonation was manually corrected for His143 (dual) of the 
active site due to mechanistic considerations and on the basis of 
results from preliminary MD simulations. Molecular mechanics 
parameters from the ff12SB and GAFF force fields, 
respectively, were assigned to the protein and the ligands using 
the LEaP module of AMBER 12.44 All terminal hydrogens 
were first minimized in vacuum (2000 steps, half of them 
steepest descent, the other half conjugate gradient). Energy 
minimization was carried out in two stages using the implicit 
solvent GB model; firstly protein side chains (2000 steps, idem) 
and secondly the entire complex (1000 steps, idem). Thereafter, 
each molecular system was immersed in a truncated octahedron 
containing TIP3P45 water molecules (10 Å radius) and Na+ 
ions46 to achieve electroneutrality. 
Simulations. MD simulations were performed using the 
AMBER 11.0 suite of programs and Amber ff12SB force field. 
Periodic boundary conditions were applied and electrostatic 
interactions were treated using the smooth particle mesh Ewald 
method (PME)47 with a grid spacing of 1 Å. The cutoff distance 
for the non-bonded interactions was 9 Å. The SHAKE 
algorithm48 was applied to all bonds containing hydrogen, using 
a tolerance of 10–5 Å and an integration step of 2.0 fs. 
Minimization was carried out in three steps, starting with the 
octahedron water hydrogens, followed by solvent molecules 
and sodium counterions and finally the entire system. The 
minimized system was heated at 300 K (1 atm, 25 ps, a 
positional restraint force constant of 50 kcal mol–1 Å–2). These 
initial harmonic restraints were gradually reduced to 5 kcal  
mol–1 Å–2 (10 steps) and the resulting systems were allowed to 
equilibrate further. MD were carried out for 10 ns. System 
coordinates were collected every 20 ps for further analysis. 
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